Skip to content
DraconiticResearch
Search Sources API
181,686 studies31 sourcesUpdated 42 min ago
Peer-reviewedCC BYJournal of Parkinson’s Disease

Rethinking the concept of disease modification in an evolving Parkinson's disease treatment landscape

  • Angelo Antonini1
  • Robert E Gross2
  • Maria De Leon3
  • Kevin Kwok4
  • Tom Foltynie5
  • Günter Höglinger6
  • Thomas Gasser7
  • Jean-Christophe Corvol8
  • David J. Pedrosa9
  • Jens Volkmann10
  • Claire Henchcliffe11
11 affiliations
  1. 1, Venice, Italy
  2. 2Robert Wood Johnson Medical School, , New Brunswick, NJ, USA
  3. 3, Nacogdoches, TX, USA
  4. 4Lived Experience Expert, , Boulder, CO, USA
  5. 5, London, UK
  6. 6Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
  7. 7, Tübingen, Germany
  8. 8University Hospitals Pitié Salpêtrière, Paris, France
  9. 9, Marburg, Germany
  10. 10, Würzburg, Germany
  11. 11, Irvine, California, USA
Read full textDOICite

Abstract

We are in an era in which increasing numbers of potentially disease-modifying treatments for Parkinson's disease are being tested in clinical development. Current definitions of disease modification have inherent limitations; hence there is a need to establish a clear, unified definition. This unified definition of disease modification should be applicable to both idiopathic and genetic forms of Parkinson's disease. In addition to motor function, it must address important milestones (e.g., cognition, autonomic dysfunction) across all disease stages. This review examines existing definitions and highlights the need for a more holistic approach that integrates the perspectives of patients, healthcare professionals, and researchers.

Related

  1. Richter Transformation of Chronic Lymphocytic Leukaemia: Biology, Diagnosis, and an Evolving Therapeutic Landscape
    Juan Marquet-Palomanes, Fernando Martin-Moro, Jose A. Garcia-Vela
    BiomedicinesPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Beyond Weight Loss: Rethinking Dietary and Lifestyle Interventions for Liver Disease Modification in MASLD.
    Abdulrahman Almujaidel, Eman Marzouk
    NutrientsPeer-reviewedCC BYFull textEpidemiology & public healthEurope PMC
  3. The Evolving Landscape of Hypertrophic Cardiomyopathy: Clinical Assessment, Precision Therapies, and Emerging Strategies
    Alessandro Parodi, Beatrice Baù, Giorgio Piccolboni +7
    Journal of Clinical MedicinePeer-reviewedCC BY 4.0General medicineCrossref
  4. Synergizing Against RAS: The Evolving Landscape of Targeted Combinations in Pancreatic Cancer
    Aditya K. Ghosh, Khalid A. Jazieh, Hao Xie +9
    CancersPeer-reviewedCC BY 4.0OncologyCrossref
  5. The Evolving Landscape of Reduced-Intensity Conditioning: Balancing Efficacy and Toxicity Across Hematologic Malignancies.
    Piyatida Chumnumsiriwath, Stefan O Ciurea, Piyanuch Kongtim
    Current hematologic malignancy reportsPeer-reviewedCC BYFull textGeneral medicineEurope PMCPMC

Cite

BibTeXRIS
BibTeX
@article{antonini2026rethinking,
  title = {{Rethinking the concept of disease modification in an evolving Parkinson's disease treatment landscape}},
  author = {Angelo Antonini and Robert E Gross and Maria De Leon and Kevin Kwok and Tom Foltynie and Günter Höglinger and Thomas Gasser and Jean-Christophe Corvol and David J. Pedrosa and Jens Volkmann and Claire Henchcliffe},
  journal = {Journal of Parkinson’s Disease},
  year = {2026},
  month = nov,
  doi = {10.1177/1877718x261481704},
  url = {https://doi.org/10.1177/1877718x261481704},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Rethinking the concept of disease modification in an evolving Parkinson's disease treatment landscape
AU  - Angelo Antonini
AU  - Robert E Gross
AU  - Maria De Leon
AU  - Kevin Kwok
AU  - Tom Foltynie
AU  - Günter Höglinger
AU  - Thomas Gasser
AU  - Jean-Christophe Corvol
AU  - David J. Pedrosa
AU  - Jens Volkmann
AU  - Claire Henchcliffe
PY  - 2026
DA  - 2026/11/04
JO  - Journal of Parkinson’s Disease
DO  - 10.1177/1877718x261481704
UR  - https://doi.org/10.1177/1877718x261481704
AB  - We are in an era in which increasing numbers of potentially disease-modifying treatments for Parkinson's disease are being tested in clinical development. Current definitions of disease modification have inherent limitations; hence there is a need to establish a clear, unified definition. This unified definition of disease modification should be applicable to both idiopathic and genetic forms of Parkinson's disease. In addition to motor function, it must address important milestones (e.g., cognition, autonomic dysfunction) across all disease stages. This review examines existing definitions and highlights the need for a more holistic approach that integrates the perspectives of patients, healthcare professionals, and researchers.
SN  - 1877-7171
SN  - 1877-718X
ER  -